

Registration

- 사전등록마감일: **2022년 11월 1일(화)**
- 사전등록신청방법
이메일: kwwf@hanmail.net
팩 스: **02-595-1549**
- 사전등록이 완료되면 확인문자를 보내드리겠습니다.

성 명		전화번호	
근무처(병원명)		핸드폰번호	
의사면허번호		이메일	

The 5th Catholic International Symposium of Gynecologic Oncology (CISGO 2022)

November 3 (Fri), 2022

 |  **한국여성암연구재단**

세빛섬 가빛 2층 Villa de noche: 서울특별시 서초구 올림픽대로 2085-14 (반포동)

Sebitseom (Gavit) (2F): 2085-14, Olympic-daero, Seocho-gu (Banpo-dong)
TEL : +82-1566-3433 | <http://www.somesevit.co.kr/kr/index.do>

The 5th Catholic International Symposium of Gynecologic Oncology (CISGO 2022)

Date: **November 3 (Thu.), 2022**

Venue: **Sebitseom (Gavit) (2F) 세빛섬 가빛**

Organized by

Department of Obstetrics & Gynecology The Catholic University of Korea
Gynecology Cancer Center, Seoul St. Mary's Hospital

Supported by

Korea Research Foundation for Gynecologic Cancer



Invitation

The 5th Catholic International Symposium of Gynecologic Oncology (CISGO 2022)



Program

13:30	Opening Remarks	Soo-Young Hur (Catholic Univ, Korea)
13:30-14:10	Session I. Immunotherapy in gynecologic cancer (Pembrolizumab, Nivolumab, Atezolizumab)	Chair: Hae-Nam Lee, Min-Jong Song (Catholic Univ, Korea)
13:30-13:50	Immunotherapy in cervical cancer	Hee-Kyung Song (Catholic Univ, Korea)
13:50-14:10	Immunotherapy in Endometrial cancer	Ji young Kim (Catholic Univ, Korea)
14:10-14:40	Immunotherapy in ovarian cancer	Min jin Jeong (Catholic Univ, Korea)
14:40-14:50	Q&A	
14:50-15:10	Coffee Break	
15:10-16:30	Session II. Special lecture	Chair: Soo-Young Hur, Keun-Ho Lee (Catholic Univ, Korea)
15:10-15:35	Transition of treatment strategy for gynecologic cancer in Japan and the treatment guidelines	Kimio Ushijima (Kurume University, Japan)
15:35-16:00	Trends and characteristics of fertility-sparing treatment for atypical endometrial hyperplasia and endometrial cancer in Japan	Naotake Tsuda (Kurume University, Japan)
16:00-16:10	Q&A	
16:10-17:10	Session III. PARPi in ovarian cancer	Chair: Yong-Seok Lee, Jin-Hwi Kim (Catholic Univ, Korea)
16:10-16:30	ESMO recommendations on predictive biomarker testing for homologous recombination	Seung Won Byun (Sun Medical Center)
16:30-16:50	PARP inhibitor in ovarian cancer maintenance therapy; PRIME vs. PRIMA	Jungwhan Ahn (Wonju Severance Christian Hospital)
16:50-17:10	CMC real world data	Boram Choi (Catholic Univ, Korea)
17:10-17:20	Q&A	
17:20	Closing Remarks	Keun-Ho Lee (Catholic Univ, Korea)

Welcome to the 5th Catholic international symposium of gynecologic oncology (CISGO 2022)

It is with great pleasure that the Division of Gynecologic Oncology of the Catholic university of Korea and Korea Research foundation for Gynecologic Cancer, invites you to attend and actively participate in the 5th Catholic international symposium of gynecologic oncology (CISGO), which will be held on the 3rd of November, 2022 at the Villa de Noche of Sevit island, Seoul, Korea. The goal of 5th CISGO is come together from all over world to enhance knowledge, accelerate skills and advance the field.

This symposium intends to comprehensively cover on current issues of gynecologic oncology. Through first session of symposium, we hope to understand the immunotherapy in gynecologic cancer. In the second session, Prof. Kimio Ushijima and Naotake Tsuda from Japan will provide you with a full update of Transition of treatment strategy for gynecologic cancer in Japan and the treatment guidelines. In last session, current use and real world data of PARP inhibitor in ovarian cancer will be discussed.

It will be a great atmosphere to interact and share a diversity of opinions and experience by the gynecologic oncologic researchers. The Catholic university of Korea and Korea Research foundation for Gynecologic Cancer request the pleasure of your company at CISGO 2022, Seoul in November 2022 and wish this symposium would be memorable to all the participants.

Keun Ho Lee

Director of division of gynecologic cancer in the Catholic university of Korea

Soo Young Hur

Chairperson of department of OBGY in the Catholic university of Korea
Chairperson of Korea Research foundation for gynecologic cancer

